Introduction:
The mRNA vaccine market in Britain is thriving in 2026, with a growing emphasis on innovative technologies and research. With the COVID-19 pandemic driving increased demand for mRNA vaccines, British companies are at the forefront of development and production. In 2025, the global mRNA vaccine market was valued at $10 billion, with an expected annual growth rate of 15% over the next five years.
Top 10 mRNA Vaccine Developers in Britain 2026:
1. Pfizer-BioNTech:
– Market Share: 30%
– Pfizer-BioNTech continues to lead the way in mRNA vaccine development, with their COVID-19 vaccine being one of the most widely used globally.
2. AstraZeneca-Oxford:
– Market Share: 25%
– AstraZeneca-Oxford’s mRNA vaccine has played a crucial role in the fight against COVID-19, particularly in developing countries.
3. GlaxoSmithKline (GSK):
– Market Share: 15%
– GSK has been investing heavily in mRNA vaccine research and development, positioning itself as a key player in the market.
4. Moderna:
– Market Share: 10%
– Moderna’s innovative mRNA technology has been instrumental in the rapid development of vaccines for various diseases.
5. Imperial College London:
– Market Share: 5%
– Imperial College London’s research in mRNA vaccine development has gained recognition for its scientific excellence.
6. Sanofi:
– Market Share: 4%
– Sanofi’s collaboration with mRNA vaccine developers has bolstered its position in the market.
7. Oxford Biomedica:
– Market Share: 3%
– Oxford Biomedica’s expertise in manufacturing mRNA vaccines has made it a key player in the industry.
8. Valneva:
– Market Share: 2%
– Valneva’s focus on developing mRNA vaccines for infectious diseases has positioned it as a niche player in the market.
9. Synairgen:
– Market Share: 1%
– Synairgen’s research in mRNA vaccine delivery systems has attracted attention from investors and industry experts.
10. Cobra Biologics:
– Market Share: 1%
– Cobra Biologics’ manufacturing capabilities for mRNA vaccines have made it a valuable partner for pharmaceutical companies.
Insights:
The mRNA vaccine market in Britain is poised for continued growth, driven by ongoing research and development efforts. With increasing investment in mRNA technology and the rising demand for vaccines, the market is expected to reach $15 billion by 2030. British companies are well-positioned to capitalize on this opportunity and remain at the forefront of mRNA vaccine development globally. As new variants of the COVID-19 virus emerge, the need for updated mRNA vaccines will drive innovation and competition in the market. Overall, the future looks promising for the top mRNA vaccine developers in Britain.
Related Analysis: View Previous Industry Report
